《大行報告》花旗對財險(02328.HK)開展30天正面催化劑觀察
花旗發表研究報告指出,監於中國財險(02328.HK)第三季業績強勁,該行對財險開展30天正面催化劑觀察,尤其是在承保方面,該行預計公司將實現承保利潤大幅增長,主要由於業務組合持續優化,汽車保費增長穩固,以及受政府扶持政策支持下,讓非汽車業務的風險選擇更爲靈活,特別是責任險和產險方面。
此外,該行認爲財險的自然災害損失程度按年有所改善,今年七至八月,內地自然災害造成的直接經濟損失按年縮減84%至716億元人民幣。
花旗又指,在內地新冠肺炎「清零」措施下,長途旅行有所減少,令財險的汽車業務綜合成本率(CoR)表現不俗。花旗對財險評級「買入」,目標價10.8元。+
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.